ANDA 76692, held by Chartwell RX. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 76692 (Amlodipine Besylate), held by Chartwell RX, was first approved by FDA on Jul 20, 2007, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2007 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Rx |
| Jan 23, 2012 | Supplement 4Labeling | Approved | None posted |
| Jul 22, 2011 | Supplement 3Labeling | Approved | None posted |
| Apr 29, 2010 | Supplement 2Labeling | Approved | None posted |
| Jul 20, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters